Baxter International Inc. (BAX) announced that it sees multiyear opportunity in H1N1 vaccines, commonly known as Swine Flu vaccines. The company expects to recognize $30 million to $40 million in revenues from swine flu vaccines in the fourth quarter. Baxter has not speculated on H1N1 vaccine sales beyond the fourth quarter. However Incorporatedreasing demand has raised hopes for a multiyear opportunity. Baxter started shipping the product from August 2009.

Baxter and four other companies Sanofi-Aventis (SNY); MedImmune, a subsidiary of AstraZeneca plc (AZN); GlaxoSmithKline plc (GSK); and Novartis have received authorization to market H1N1 vaccines. Baxter has received approval only for a two-dose vaccine and not a single-dose. Baxter uses its cell culture-based technology instead of the traditional one to produce these vaccines.

Baxter recently announced strong third quarter results. Earnings per share stood at 98 cents, surpassing the Zacks Consensus Estimate of 97 cents and the year-ago earnings of 88 cents. Net sales were $3.1 billion, roughly flat year over year. However, excluding the unfavorable foreign currency translation, net sales increased approximately 6% year over year. The company also witnessed an expansion in margins.

Baxter is a leading global medical products and services company that develops, manufactures and markets products to save the lives of millions of people affected by hemophilia, kidney disease, infectious diseases, etc. Baxter’s main competitors include Becton, Dickinson and Co. (BDX) and Johnson & Johnson (JNJ). Baxter’s products are primarily life-sustaining, a hedge against the current economic turmoil.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (BAX) Baxter International Beats Earnings, Raises OutlookBaxter International Inc. (BAX) today reported third quarter fiscal 2009 earnings per share of 98...
2. (BAX) Baxter International Gets H1N1 AuthorizationBaxter International Inc. (BAX) recently received marketing authorization for CELVAPAN H1N1 vaccine, commonly known as...
3. ($GSK) GlaxoSmithKline Announces Swine Flu Vaccine Orders IncreaseYesterday, GlaxoSmithKline (GSK) announced that orders for its pandemic (H1N1) adjuvanted vaccine have increased significantly...
4. (BAX) Baxter International’s H1N1 Vaccine Gets a BoostBaxter International Inc. (BAX) announced that the European Medicines Agency (EMEA) opined positively for Baxter’s...
5. (BAX) Baxter International Discussed Long-Term GoalsBaxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and...
6. (BAX) Baxter International Fails to Deliver Swine Flu VaccineBaxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government...

Search Posts by Tag: AstraZeneca plc | AZN | BAX | Baxter International Inc | BDX | Becton | Dickinson And Company | Glaxosmithkline plc | GSK | JNJ | Johnson & Johnson | Sanofi-Aventis | SNY | Healthcare

RSS Feeds by Tag: AstraZeneca plc | AZN | BAX | Baxter International Inc | BDX | Becton | Dickinson And Company | Glaxosmithkline plc | GSK | JNJ | Johnson & Johnson | Sanofi-Aventis | SNY | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author